NorthWest Biotherapeutics Inc (NWBO)

[brazen22]

I agree these steps show commercial intent. I do not agree that they prove near term approval or direct positive MHRA signals.

That is the distinction.

U.S. tech transfer, SOP adaptation, training, validation runs, Sawston expansion, leukapheresis capacity, and Flaskworks integration are all consistent with a company preparing for commercialization. But they are also consistent with a company trying to satisfy manufacturing, CMC, validation, comparability, and capacity requirements that may still be unresolved.

That is why I do not treat these actions as proof that approval is close. They may be required steps to keep the approval path alive.

A cash constrained company can still make expensive moves if the alternative is worse. If NWBO cannot demonstrate credible commercial manufacturing readiness, then the MAA may not be approvable. So the spend may not mean “approval is assured.” It may mean “without this spend, approval is impossible.”

On your question, I would say these steps look more like near term commercial intent than a company planning to sit idle for 2 to 3 years. But intent is not approval. Preparation is not clearance. And expensive preparation is not proof of positive non public regulatory signals.

It tells me management believes they need to be ready. It does not tell me MHRA has already signaled the outcome.

You say a rational management team would not spend that kind of money unless it had high conviction based on direct regulatory feedback that approval is close. But if that regulatory feedback is strong enough to justify saying approval is close, then it sounds material.

If NWBO had received a definite or near definite positive signal from MHRA, that would seem like material information. If the feedback is not material enough to disclose, then I do not see how it is strong enough to support message board certainty that approval is on the way.

Routine regulatory feedback, RFIs, CMC questions, inspection issues, validation questions, and manufacturing readiness discussions can explain expensive preparation without proving approval is close. They may show what NWBO still has to satisfy, not what MHRA has already decided.